EGFR – Epidemiology – Mature Markets
UNDERSTAND THE TOTAL MARKET SIZE AND TREATMENT OPPORTUNITIES FOR BIOMARKERS
The development of biomarker-driven therapies continues to be a major trend in oncology. As biomarkers are often clinically relevant in more than one indication, the concept of sizing eligible patient populations is evolving. With DRG Biomarker Epidemiology data and insights, the entire biomarker-defined population can be sized in minutes.
| EGFR | KRAS | BRCA | ALK | |
|---|---|---|---|---|
| Breast cancer | x | x | x | |
| Renal cell carinoma | x | |||
| Ovarian cancer | x | |||
| Prostate cancer | x | |||
| Pancreatic cancer | x | x | ||
| Colorectal cancer | x | x | x | |
| Non-small-cell lung cancer | x | x | x | |
| Head and neck cancer | x | |||
| Thyroid carcinoma | x | |||
| Small-cell lung cancer | x | |||
| Rare tumors | x | x | ||
| Source: Clarivate | ||||
FIRST-LINE DRUG-TREATABLE EGFR POPULATIONS
Breast cancer
Non-small-cell lung cancer
Small-cell lung cancer
Squamous cell carcinoma of the head and neck
Colorectal cancer
EPIDEMIOLOGY IS THE FOUNDATION OF MARKET FORECASTING AT ALL PHASES OF PRODUCT DEVELOPMENT AND STRATEGY
You need biomarker epidemiology data that you can trust in order to:
- Complete biomarker-driven market-sizing assessments based on patient population sizes and patient flows.
- Build the foundation of a market forecast for strategic planning for biomarker-targeting for new and existing assets.
- Understand how the patient populations for certain biomarkers will evolve over time.
- Answer any question you may have about specific subpopulations, biomarkers, and the impact of new studies.
Table of contents
- EGFR - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Diagnosed Incidence of EGFR-Mutated Cancers per 100,000 People of All Ages in 2021 and 2031
- Patient-Flow Diagram of EGFR-Mutated Cancers in the Major Mature Pharmaceutical Markets in 2021
- Analysis of the Diagnosed Incidence of EGFR-Mutated Cancers in 2021 by Cancer Site
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed EGFR-Mutated Incident Cases
- Diagnosed EGFR-Mutated NSCLC Incident Cases
- Diagnosed EGFR-Mutated SCLC Incident Cases
- Diagnosed EGFR-Mutated SCCHN Incident Cases
- Diagnosed EGFR-Mutated Breast Cancer Incident Cases
- Diagnosed EGFR-Mutated Colorectal Cancer Incident Cases
- Diagnosed EGFR-Mutated Glioblastoma Incident Cases
- Diagnosed EGFR-Mutated First-Line Drug-Treatable Population
- Diagnosed EGFR-Mutated NSCLC First-Line Drug-Treatable Population
- Diagnosed EGFR-Mutated SCLC First-Line Drug-Treatable Population
- Diagnosed EGFR-Mutated SCCHN First-Line Drug-Treatable Population
- Diagnosed EGFR-Mutated Breast Cancer First-Line Drug-Treatable Population
- Diagnosed EGFR-Mutated Colorectal Cancer First-Line Drug-Treatable Population
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Diagnosed Incident Cases
- Studies Excluded in the Analysis of Diagnosed Incident Cases
- Risk/Protective Factors
- Bibliography
- Abbreviations
- Glossary
- Literature Review
- Introduction
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.